Name: Bavisant dihydrochloride hydrate
Rating: 5 (10 reviews)

有库存

sdf 文件

结构编辑

类似物检索

HIT ID:HIT212669427
Cas No:1103522-80-0
常用名:Bavisant dihydrochloride hydrate
常用名:Bavisant dihydrochloride hydrate
别名:JNJ31001074AAC
IUPAC:4-{[4-(4-cyclopropylpiperazine-1-carbonyl)phenyl]methyl}morpholine hydrate dihydrochloride
IUPAC:4-{[4-(4-cyclopropylpiperazine-1-carbonyl)phenyl]methyl}morpholine hydrate dihydrochloride
InChI key:BLFBQJUVAGIUBL-UHFFFAOYSA-N

分子式:C19H31Cl2N3O3
分子量:420.38
氢键供体数 (HBD):0
氢键受体数 (HBA):4
LogP:1.3068187
SMILES:O.Cl.Cl.O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1
SMILES:O.Cl.Cl.O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1

Bavisant dihydrochloride hydrate (JNJ31001074AAC) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD. in vivo: Mean change from baseline in the total ADHD-RS-IV score at day 42 (primary efficacy endpoint) was -8.8 in the placebo group versus -9.3, -11.2 and -12.2 in the bavisant 1 mg/day, 3 mg/day and 10 mg/day groups, respectively; the change in the 10 mg/day group was not statistically superior to placebo (p=0.161). IC50 Value: Target: H3 receptor in vitro: Bavisant completed a phase II ADHD trial, but no results have been reported [1]. And hence statistical comparisons of the 1 mg/day and 3 mg/day groups with placebo based on a step-down closed testing procedure were not performed [2]. Clinical trial: A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers. Phase 2

市场产品/服务共显示2个结果

您无法确定哪种化合物库最适合您的项目？或者您需要定制解决方案？Anymole随时为您提供帮助。

电话：400820-0310

合作：info@screeningcompound.com

技术支持：tech@screeningcompound.com

客服：service@screeningcompound.com

正在加载 ~